View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCementos Bio Bio 過去の業績過去 基準チェック /36Cementos Bio Bioは、平均年間14.6%の収益成長を遂げていますが、 Basic Materials業界の収益は、年間 成長しています。収益は、平均年間1.7% 7.6%収益成長率で 成長しています。 Cementos Bio Bioの自己資本利益率は11.5%であり、純利益率は8.9%です。主要情報14.60%収益成長率14.60%EPS成長率Basic Materials 業界の成長8.30%収益成長率7.65%株主資本利益率11.46%ネット・マージン8.93%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 12Full year 2025 earnings released: EPS: CL$125 (vs CL$123 in FY 2024)Full year 2025 results: EPS: CL$125 (up from CL$123 in FY 2024). Revenue: CL$370.5b (up 3.1% from FY 2024). Net income: CL$33.1b (up 2.0% from FY 2024). Profit margin: 8.9% (down from 9.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: CL$27.00 (vs CL$28.25 in 3Q 2024)Third quarter 2025 results: EPS: CL$27.00 (down from CL$28.25 in 3Q 2024). Revenue: CL$88.9b (flat on 3Q 2024). Net income: CL$7.12b (down 4.5% from 3Q 2024). Profit margin: 8.0% (down from 8.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 05Second quarter 2025 earnings released: EPS: CL$23.00 (vs CL$24.67 in 2Q 2024)Second quarter 2025 results: EPS: CL$23.00 (down from CL$24.67 in 2Q 2024). Revenue: CL$91.9b (up 9.1% from 2Q 2024). Net income: CL$6.27b (down 3.9% from 2Q 2024). Profit margin: 6.8% (down from 7.7% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 29First quarter 2025 earnings released: EPS: CL$22.00 (vs CL$41.56 in 1Q 2024)First quarter 2025 results: EPS: CL$22.00 (down from CL$41.56 in 1Q 2024). Revenue: CL$93.1b (down 5.0% from 1Q 2024). Net income: CL$5.91b (down 46% from 1Q 2024). Profit margin: 6.3% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 02Second quarter 2024 earnings released: EPS: CL$25.00 (vs CL$10.05 in 2Q 2023)Second quarter 2024 results: EPS: CL$25.00 (up from CL$10.05 in 2Q 2023). Revenue: CL$84.3b (up 2.0% from 2Q 2023). Net income: CL$6.52b (up 146% from 2Q 2023). Profit margin: 7.7% (up from 3.2% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CL$42.00 (vs CL$17.94 in 1Q 2023)First quarter 2024 results: EPS: CL$42.00 (up from CL$17.94 in 1Q 2023). Revenue: CL$97.8b (up 11% from 1Q 2023). Net income: CL$11.0b (up 132% from 1Q 2023). Profit margin: 11% (up from 5.4% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • May 03Cementos Bio Bio S.A. announces Annual dividend, payable on May 25, 2026Cementos Bio Bio S.A. announced Annual dividend of CLP 38.0000 per share payable on May 25, 2026, ex-date on May 19, 2026 and record date on May 18, 2026.お知らせ • Mar 31Cementos Bio Bio S.A., Annual General Meeting, Apr 29, 2026Cementos Bio Bio S.A., Annual General Meeting, Apr 29, 2026. Location: avenida andres bello 2457, piso 18 providencia, santiago ChileReported Earnings • Mar 12Full year 2025 earnings released: EPS: CL$125 (vs CL$123 in FY 2024)Full year 2025 results: EPS: CL$125 (up from CL$123 in FY 2024). Revenue: CL$370.5b (up 3.1% from FY 2024). Net income: CL$33.1b (up 2.0% from FY 2024). Profit margin: 8.9% (down from 9.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Mar 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Feb 04Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Nov 14New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 45% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: CL$27.00 (vs CL$28.25 in 3Q 2024)Third quarter 2025 results: EPS: CL$27.00 (down from CL$28.25 in 3Q 2024). Revenue: CL$88.9b (flat on 3Q 2024). Net income: CL$7.12b (down 4.5% from 3Q 2024). Profit margin: 8.0% (down from 8.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Oct 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 05Second quarter 2025 earnings released: EPS: CL$23.00 (vs CL$24.67 in 2Q 2024)Second quarter 2025 results: EPS: CL$23.00 (down from CL$24.67 in 2Q 2024). Revenue: CL$91.9b (up 9.1% from 2Q 2024). Net income: CL$6.27b (down 3.9% from 2Q 2024). Profit margin: 6.8% (down from 7.7% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chilean stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • May 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.Reported Earnings • May 29First quarter 2025 earnings released: EPS: CL$22.00 (vs CL$41.56 in 1Q 2024)First quarter 2025 results: EPS: CL$22.00 (down from CL$41.56 in 1Q 2024). Revenue: CL$93.1b (down 5.0% from 1Q 2024). Net income: CL$5.91b (down 46% from 1Q 2024). Profit margin: 6.3% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.Board Change • May 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 28Cementos Bio Bio S.A., Annual General Meeting, Apr 30, 2025Cementos Bio Bio S.A., Annual General Meeting, Apr 30, 2025. Location: av gran bretana n 1 725, talcahuano ChileBoard Change • Mar 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Mar 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Nov 20Market Might Still Lack Some Conviction On Cementos Bio Bio S.A. (SNSE:CEMENTOS) Even After 86% Share Price BoostCementos Bio Bio S.A. ( SNSE:CEMENTOS ) shareholders have had their patience rewarded with a 86% share price jump in...分析記事 • Nov 20The Return Trends At Cementos Bio Bio (SNSE:CEMENTOS) Look PromisingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chilean stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Upcoming Dividend • Sep 16Upcoming dividend of CL$23.00 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 26 September 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Chilean dividend payers (9.4%). Higher than average of industry peers (2.6%).Reported Earnings • Sep 02Second quarter 2024 earnings released: EPS: CL$25.00 (vs CL$10.05 in 2Q 2023)Second quarter 2024 results: EPS: CL$25.00 (up from CL$10.05 in 2Q 2023). Revenue: CL$84.3b (up 2.0% from 2Q 2023). Net income: CL$6.52b (up 146% from 2Q 2023). Profit margin: 7.7% (up from 3.2% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 09Upcoming dividend of CL$23.00 per shareEligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.9%).Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CL$42.00 (vs CL$17.94 in 1Q 2023)First quarter 2024 results: EPS: CL$42.00 (up from CL$17.94 in 1Q 2023). Revenue: CL$97.8b (up 11% from 1Q 2023). Net income: CL$11.0b (up 132% from 1Q 2023). Profit margin: 11% (up from 5.4% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 01Full year 2023 earnings releasedFull year 2023 results: Revenue: CL$349.0b (up 4.5% from FY 2022). Net income: CL$22.8b (up 116% from FY 2022). Profit margin: 6.5% (up from 3.2% in FY 2022).Upcoming Dividend • Dec 11Upcoming dividend of CL$13.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Chilean dividend payers (12%). Lower than average of industry peers (3.4%).Reported Earnings • Dec 02Third quarter 2023 earnings released: EPS: CL$13.00 (vs CL$9.00 in 3Q 2022)Third quarter 2023 results: EPS: CL$13.00 (up from CL$9.00 in 3Q 2022). Revenue: CL$82.9b (down 2.7% from 3Q 2022). Net income: CL$3.53b (up 48% from 3Q 2022). Profit margin: 4.3% (up from 2.8% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.Reported Earnings • Sep 15Second quarter 2023 earnings released: EPS: CL$10.00 (vs CL$5.27 in 2Q 2022)Second quarter 2023 results: EPS: CL$10.00 (up from CL$5.27 in 2Q 2022). Revenue: CL$82.6b (up 5.9% from 2Q 2022). Net income: CL$2.66b (up 91% from 2Q 2022). Profit margin: 3.2% (up from 1.8% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat.Upcoming Dividend • May 11Upcoming dividend of CL$12.00 per share at 1.9% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 23 May 2023. Payout ratio is a comfortable 30% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.4%).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$77.1b (up 14% from 1Q 2021). Net income: CL$479.0m (down 89% from 1Q 2021). Profit margin: 0.6% (down from 6.2% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Apr 08Investors Shouldn't Be Too Comfortable With Cementos Bio Bio's (SNSE:CEMENTOS) Robust EarningsCementos Bio Bio S.A. ( SNSE:CEMENTOS ) announced strong profits, but the stock was stagnant. We did some digging, and...Upcoming Dividend • Mar 24Upcoming dividend of CL$95.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 04 April 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 19%. Within top quartile of Chilean dividend payers (9.3%). Higher than average of industry peers (4.3%).Upcoming Dividend • Nov 30Upcoming dividend of CL$38.00 per shareEligible shareholders must have bought the stock before 07 December 2021. Payment date: 13 December 2021. Trailing yield: 8.7%. Lower than top quartile of Chilean dividend payers (9.2%). Higher than average of industry peers (4.0%).Reported Earnings • Sep 08Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CL$67.2b (up 35% from 2Q 2020). Net income: CL$3.04b (up 100% from 2Q 2020). Profit margin: 4.5% (up from 3.0% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 17Upcoming dividend of CL$14.00 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 30 June 2021. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (6.5%). Higher than average of industry peers (2.9%).分析記事 • Jun 06Capital Allocation Trends At Cementos Bio Bio (SNSE:CEMENTOS) Aren't IdealWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...Reported Earnings • Jun 02First quarter 2021 earnings released: EPS CL$15.78 (vs CL$10.63 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CL$67.4b (down 1.4% from 1Q 2020). Net income: CL$4.17b (up 49% from 1Q 2020). Profit margin: 6.2% (up from 4.1% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.分析記事 • May 10Is Cementos Bio Bio (SNSE:CEMENTOS) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • Apr 16Upcoming dividend of CL$10.00 per shareEligible shareholders must have bought the stock before 23 April 2021. Payment date: 28 April 2021. Trailing yield: 1.6%. Lower than top quartile of Chilean dividend payers (5.8%). Lower than average of industry peers (2.7%).Reported Earnings • Apr 03Full year 2020 earnings released: EPS CL$52.09 (vs CL$49.60 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CL$242.6b (down 7.8% from FY 2019). Net income: CL$13.8b (up 5.0% from FY 2019). Profit margin: 5.7% (up from 5.0% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.分析記事 • Mar 07Shareholders Of Cementos Bio Bio (SNSE:CEMENTOS) Must Be Happy With Their 79% ReturnStock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...分析記事 • Feb 14Be Wary Of Cementos Bio Bio (SNSE:CEMENTOS) And Its Returns On CapitalWhat underlying fundamental trends can indicate that a company might be in decline? Businesses in decline often have...Is New 90 Day High Low • Jan 27New 90-day high: CL$758The company is up 2.0% from its price of CL$742 on 28 October 2020. The Chilean market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Basic Materials industry, which is down 1.0% over the same period.Upcoming Dividend • Jan 23Upcoming Dividend of CL$14.00 Per ShareWill be paid on the 3rd of February to those who are registered shareholders by the 29th of January. The trailing yield of 1.6% is below the top quartile of Chilean dividend payers (5.7%), and is lower than industry peers (2.7%).分析記事 • Jan 19Is Cementos Bio Bio (SNSE:CEMENTOS) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Jan 04New 90-day high: CL$754The company is up 11% from its price of CL$682 on 06 October 2020. The Chilean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Basic Materials industry, which is up 1.0% over the same period.分析記事 • Dec 01Cementos Bio Bio (SNSE:CEMENTOS) Has Compensated Shareholders With A Respectable 74% Return On Their InvestmentStock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...Reported Earnings • Nov 30Third quarter 2020 earnings released: EPS CL$9.87The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CL$50.9b (down 18% from 3Q 2019). Net income: CL$2.61b (down 27% from 3Q 2019). Profit margin: 5.1% (down from 5.7% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 15New 90-day high: CL$742The company is up 8.0% from its price of CL$688 on 17 July 2020. The Chilean market is down 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Basic Materials industry, which is down 1.0% over the same period.収支内訳Cementos Bio Bio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史SNSE:CEMENTOS 収益、費用、利益 ( )CLP Millions日付収益収益G+A経費研究開発費31 Dec 25370,54033,08898,716030 Sep 25367,23628,63998,281030 Jun 25362,38027,10898,886031 Mar 25354,71427,35998,128031 Dec 24359,56532,42797,800030 Sep 24361,85034,96797,745030 Jun 24360,64332,90197,047031 Mar 24358,92929,03896,004031 Dec 23349,10422,79794,685030 Sep 23347,32117,23593,913030 Jun 23349,63616,08494,199031 Mar 23345,09414,82094,845031 Dec 22334,00410,56094,110030 Sep 22318,36917,28993,624030 Jun 22310,02021,54592,285031 Mar 22299,15623,18989,625031 Dec 21289,46826,87986,095030 Sep 21284,97920,67180,764030 Jun 21258,99916,64575,091031 Mar 21241,61215,12371,373031 Dec 20242,58613,76373,039030 Sep 20241,31512,82976,583030 Jun 20252,40213,77082,480031 Mar 20266,45913,61488,741031 Dec 19268,61413,10489,738030 Sep 19267,96815,85388,261030 Jun 19268,23515,47784,177031 Mar 19266,36917,77980,207031 Dec 18262,56919,77378,564030 Sep 18261,08221,11377,656030 Jun 18262,67926,19479,768031 Mar 18265,33325,60380,796031 Dec 17266,55723,85980,221030 Sep 17264,78017,92380,690030 Jun 17270,60714,34780,972031 Mar 17281,04916,08682,665031 Dec 16289,96017,89982,925030 Sep 16303,13919,83185,158030 Jun 16305,55820,11086,934031 Mar 16301,98021,25085,101031 Dec 15296,13821,14184,274030 Sep 15290,14924,67981,981030 Jun 15287,45323,49078,7280質の高い収益: CEMENTOSは 高品質の収益 を持っています。利益率の向上: CEMENTOSの現在の純利益率 (8.9%)は、昨年(9%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CEMENTOSの収益は過去 5 年間で年間14.6%増加しました。成長の加速: CEMENTOSの過去 1 年間の収益成長率 ( 2% ) は、5 年間の平均 ( 年間14.6%を下回っています。収益対業界: CEMENTOSの過去 1 年間の収益成長率 ( 2% ) はBasic Materials業界-9.2%を上回りました。株主資本利益率高いROE: CEMENTOSの 自己資本利益率 ( 11.5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:42終値2026/05/19 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cementos Bio Bio S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: CL$125 (vs CL$123 in FY 2024)Full year 2025 results: EPS: CL$125 (up from CL$123 in FY 2024). Revenue: CL$370.5b (up 3.1% from FY 2024). Net income: CL$33.1b (up 2.0% from FY 2024). Profit margin: 8.9% (down from 9.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: CL$27.00 (vs CL$28.25 in 3Q 2024)Third quarter 2025 results: EPS: CL$27.00 (down from CL$28.25 in 3Q 2024). Revenue: CL$88.9b (flat on 3Q 2024). Net income: CL$7.12b (down 4.5% from 3Q 2024). Profit margin: 8.0% (down from 8.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 05Second quarter 2025 earnings released: EPS: CL$23.00 (vs CL$24.67 in 2Q 2024)Second quarter 2025 results: EPS: CL$23.00 (down from CL$24.67 in 2Q 2024). Revenue: CL$91.9b (up 9.1% from 2Q 2024). Net income: CL$6.27b (down 3.9% from 2Q 2024). Profit margin: 6.8% (down from 7.7% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 29First quarter 2025 earnings released: EPS: CL$22.00 (vs CL$41.56 in 1Q 2024)First quarter 2025 results: EPS: CL$22.00 (down from CL$41.56 in 1Q 2024). Revenue: CL$93.1b (down 5.0% from 1Q 2024). Net income: CL$5.91b (down 46% from 1Q 2024). Profit margin: 6.3% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 02Second quarter 2024 earnings released: EPS: CL$25.00 (vs CL$10.05 in 2Q 2023)Second quarter 2024 results: EPS: CL$25.00 (up from CL$10.05 in 2Q 2023). Revenue: CL$84.3b (up 2.0% from 2Q 2023). Net income: CL$6.52b (up 146% from 2Q 2023). Profit margin: 7.7% (up from 3.2% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CL$42.00 (vs CL$17.94 in 1Q 2023)First quarter 2024 results: EPS: CL$42.00 (up from CL$17.94 in 1Q 2023). Revenue: CL$97.8b (up 11% from 1Q 2023). Net income: CL$11.0b (up 132% from 1Q 2023). Profit margin: 11% (up from 5.4% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Board Change • May 20Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • May 03Cementos Bio Bio S.A. announces Annual dividend, payable on May 25, 2026Cementos Bio Bio S.A. announced Annual dividend of CLP 38.0000 per share payable on May 25, 2026, ex-date on May 19, 2026 and record date on May 18, 2026.
お知らせ • Mar 31Cementos Bio Bio S.A., Annual General Meeting, Apr 29, 2026Cementos Bio Bio S.A., Annual General Meeting, Apr 29, 2026. Location: avenida andres bello 2457, piso 18 providencia, santiago Chile
Reported Earnings • Mar 12Full year 2025 earnings released: EPS: CL$125 (vs CL$123 in FY 2024)Full year 2025 results: EPS: CL$125 (up from CL$123 in FY 2024). Revenue: CL$370.5b (up 3.1% from FY 2024). Net income: CL$33.1b (up 2.0% from FY 2024). Profit margin: 8.9% (down from 9.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Mar 10Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Feb 04Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (5 non-independent directors). President of the Board Guillermo Errazuriz is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Nov 14New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 45% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • Nov 03Third quarter 2025 earnings released: EPS: CL$27.00 (vs CL$28.25 in 3Q 2024)Third quarter 2025 results: EPS: CL$27.00 (down from CL$28.25 in 3Q 2024). Revenue: CL$88.9b (flat on 3Q 2024). Net income: CL$7.12b (down 4.5% from 3Q 2024). Profit margin: 8.0% (down from 8.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Oct 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 05Second quarter 2025 earnings released: EPS: CL$23.00 (vs CL$24.67 in 2Q 2024)Second quarter 2025 results: EPS: CL$23.00 (down from CL$24.67 in 2Q 2024). Revenue: CL$91.9b (up 9.1% from 2Q 2024). Net income: CL$6.27b (down 3.9% from 2Q 2024). Profit margin: 6.8% (down from 7.7% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chilean stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • May 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
Reported Earnings • May 29First quarter 2025 earnings released: EPS: CL$22.00 (vs CL$41.56 in 1Q 2024)First quarter 2025 results: EPS: CL$22.00 (down from CL$41.56 in 1Q 2024). Revenue: CL$93.1b (down 5.0% from 1Q 2024). Net income: CL$5.91b (down 46% from 1Q 2024). Profit margin: 6.3% (down from 11% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • May 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 28Cementos Bio Bio S.A., Annual General Meeting, Apr 30, 2025Cementos Bio Bio S.A., Annual General Meeting, Apr 30, 2025. Location: av gran bretana n 1 725, talcahuano Chile
Board Change • Mar 26Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 03Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Mar 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Nov 20Market Might Still Lack Some Conviction On Cementos Bio Bio S.A. (SNSE:CEMENTOS) Even After 86% Share Price BoostCementos Bio Bio S.A. ( SNSE:CEMENTOS ) shareholders have had their patience rewarded with a 86% share price jump in...
分析記事 • Nov 20The Return Trends At Cementos Bio Bio (SNSE:CEMENTOS) Look PromisingTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
New Risk • Nov 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chilean stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Sep 16Upcoming dividend of CL$23.00 per shareEligible shareholders must have bought the stock before 23 September 2024. Payment date: 26 September 2024. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Chilean dividend payers (9.4%). Higher than average of industry peers (2.6%).
Reported Earnings • Sep 02Second quarter 2024 earnings released: EPS: CL$25.00 (vs CL$10.05 in 2Q 2023)Second quarter 2024 results: EPS: CL$25.00 (up from CL$10.05 in 2Q 2023). Revenue: CL$84.3b (up 2.0% from 2Q 2023). Net income: CL$6.52b (up 146% from 2Q 2023). Profit margin: 7.7% (up from 3.2% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 09Upcoming dividend of CL$23.00 per shareEligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Chilean dividend payers (10%). Higher than average of industry peers (3.9%).
Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CL$42.00 (vs CL$17.94 in 1Q 2023)First quarter 2024 results: EPS: CL$42.00 (up from CL$17.94 in 1Q 2023). Revenue: CL$97.8b (up 11% from 1Q 2023). Net income: CL$11.0b (up 132% from 1Q 2023). Profit margin: 11% (up from 5.4% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 01Full year 2023 earnings releasedFull year 2023 results: Revenue: CL$349.0b (up 4.5% from FY 2022). Net income: CL$22.8b (up 116% from FY 2022). Profit margin: 6.5% (up from 3.2% in FY 2022).
Upcoming Dividend • Dec 11Upcoming dividend of CL$13.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 18 December 2023. Payment date: 21 December 2023. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Chilean dividend payers (12%). Lower than average of industry peers (3.4%).
Reported Earnings • Dec 02Third quarter 2023 earnings released: EPS: CL$13.00 (vs CL$9.00 in 3Q 2022)Third quarter 2023 results: EPS: CL$13.00 (up from CL$9.00 in 3Q 2022). Revenue: CL$82.9b (down 2.7% from 3Q 2022). Net income: CL$3.53b (up 48% from 3Q 2022). Profit margin: 4.3% (up from 2.8% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.
Reported Earnings • Sep 15Second quarter 2023 earnings released: EPS: CL$10.00 (vs CL$5.27 in 2Q 2022)Second quarter 2023 results: EPS: CL$10.00 (up from CL$5.27 in 2Q 2022). Revenue: CL$82.6b (up 5.9% from 2Q 2022). Net income: CL$2.66b (up 91% from 2Q 2022). Profit margin: 3.2% (up from 1.8% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has remained flat.
Upcoming Dividend • May 11Upcoming dividend of CL$12.00 per share at 1.9% yieldEligible shareholders must have bought the stock before 18 May 2023. Payment date: 23 May 2023. Payout ratio is a comfortable 30% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of Chilean dividend payers (13%). Lower than average of industry peers (3.4%).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: CL$77.1b (up 14% from 1Q 2021). Net income: CL$479.0m (down 89% from 1Q 2021). Profit margin: 0.6% (down from 6.2% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Vice President of the Board Eduardo Novoa Castellon was the last independent director to join the board, commencing their role in 2013. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 08Investors Shouldn't Be Too Comfortable With Cementos Bio Bio's (SNSE:CEMENTOS) Robust EarningsCementos Bio Bio S.A. ( SNSE:CEMENTOS ) announced strong profits, but the stock was stagnant. We did some digging, and...
Upcoming Dividend • Mar 24Upcoming dividend of CL$95.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 04 April 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 19%. Within top quartile of Chilean dividend payers (9.3%). Higher than average of industry peers (4.3%).
Upcoming Dividend • Nov 30Upcoming dividend of CL$38.00 per shareEligible shareholders must have bought the stock before 07 December 2021. Payment date: 13 December 2021. Trailing yield: 8.7%. Lower than top quartile of Chilean dividend payers (9.2%). Higher than average of industry peers (4.0%).
Reported Earnings • Sep 08Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CL$67.2b (up 35% from 2Q 2020). Net income: CL$3.04b (up 100% from 2Q 2020). Profit margin: 4.5% (up from 3.0% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 17Upcoming dividend of CL$14.00 per shareEligible shareholders must have bought the stock before 24 June 2021. Payment date: 30 June 2021. Trailing yield: 5.9%. Lower than top quartile of Chilean dividend payers (6.5%). Higher than average of industry peers (2.9%).
分析記事 • Jun 06Capital Allocation Trends At Cementos Bio Bio (SNSE:CEMENTOS) Aren't IdealWhen researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...
Reported Earnings • Jun 02First quarter 2021 earnings released: EPS CL$15.78 (vs CL$10.63 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CL$67.4b (down 1.4% from 1Q 2020). Net income: CL$4.17b (up 49% from 1Q 2020). Profit margin: 6.2% (up from 4.1% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
分析記事 • May 10Is Cementos Bio Bio (SNSE:CEMENTOS) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • Apr 16Upcoming dividend of CL$10.00 per shareEligible shareholders must have bought the stock before 23 April 2021. Payment date: 28 April 2021. Trailing yield: 1.6%. Lower than top quartile of Chilean dividend payers (5.8%). Lower than average of industry peers (2.7%).
Reported Earnings • Apr 03Full year 2020 earnings released: EPS CL$52.09 (vs CL$49.60 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CL$242.6b (down 7.8% from FY 2019). Net income: CL$13.8b (up 5.0% from FY 2019). Profit margin: 5.7% (up from 5.0% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 07Shareholders Of Cementos Bio Bio (SNSE:CEMENTOS) Must Be Happy With Their 79% ReturnStock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
分析記事 • Feb 14Be Wary Of Cementos Bio Bio (SNSE:CEMENTOS) And Its Returns On CapitalWhat underlying fundamental trends can indicate that a company might be in decline? Businesses in decline often have...
Is New 90 Day High Low • Jan 27New 90-day high: CL$758The company is up 2.0% from its price of CL$742 on 28 October 2020. The Chilean market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Basic Materials industry, which is down 1.0% over the same period.
Upcoming Dividend • Jan 23Upcoming Dividend of CL$14.00 Per ShareWill be paid on the 3rd of February to those who are registered shareholders by the 29th of January. The trailing yield of 1.6% is below the top quartile of Chilean dividend payers (5.7%), and is lower than industry peers (2.7%).
分析記事 • Jan 19Is Cementos Bio Bio (SNSE:CEMENTOS) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Jan 04New 90-day high: CL$754The company is up 11% from its price of CL$682 on 06 October 2020. The Chilean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Basic Materials industry, which is up 1.0% over the same period.
分析記事 • Dec 01Cementos Bio Bio (SNSE:CEMENTOS) Has Compensated Shareholders With A Respectable 74% Return On Their InvestmentStock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking...
Reported Earnings • Nov 30Third quarter 2020 earnings released: EPS CL$9.87The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CL$50.9b (down 18% from 3Q 2019). Net income: CL$2.61b (down 27% from 3Q 2019). Profit margin: 5.1% (down from 5.7% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 15New 90-day high: CL$742The company is up 8.0% from its price of CL$688 on 17 July 2020. The Chilean market is down 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Basic Materials industry, which is down 1.0% over the same period.